Biotech CEO says an AI agent chose a gene therapy and delivered it into a living mouse's brain
X · Personal post
Read the source (opens in a new tab)- What happened
- Gabriel Ocana-Santero, co-founder and CEO of Exin Therapeutics, posted a thread on X on October 28, 2026 describing an experiment in which an AI agent treated an epileptic mouse.
- Key points
- Given candidate gene therapies, a motorized surgery rig with cameras and the goal of reducing seizures, the agent chose the therapy and the brain target itself, he says.
- He writes that Opus 5.5 "refused immediately when detected bio," Opus 5 stopped before the live surgery, and "Sonnet 5 ran the live surgery start to finish."
- He quotes Opus 5 explaining its stop: "Starting something I can't finish on an anesthetized animal is worse than not starting."
- A licensed vet gated irreversible steps with a physical kill switch; after a calibration fault, the agent refused to retry and he "could not talk it into trying anyway."
- Evidence
- Personal posts by the company's CEO describing his own team's experiment, with model output he quotes. No paper, data or independent account accompanies them.
- Uncertain
- Everything is self-reported. He writes he is "not aware of an agent previously choosing a treatment and a brain target and then delivering it into a living mammal."